Rosetta Genomics Ltd (ROSGQ)

Rosetta Genomics Ltd is a common stock listing on OTC Markets representing a healthcare company focused on genomic diagnostics. The company develops microRNA-based and other molecular tests used in cancer and pathology settings, including products for identifying the primary site of metastatic cancer, classifying kidney tumors, supporting thyroid nodule diagnosis, and testing for lung, bladder, prostate, colon, and melanoma-related conditions. Its portfolio also includes FISH-based assays such as UroVysion, ERG/PTEN, and ALK/ROS1, which are used alongside standard diagnostic procedures. Rosetta Genomics serves clinicians including oncologists, urologists, endocrinologists, and cytopathologists. The company has a license agreement with Max Planck Innovation GmbH covering proprietary microRNAs for diagnostics and research, and a collaboration with Meir Medical Center focused on a microRNA classifier for non-small cell lung cancer treatment research. Founded in 2000, the company is headquartered in Rehovot, Israel.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.